Abstract
Background:
Soft
Tissue Sarcomas (STS) are rare malignant tumors of mesenchymal origin, most
frequently arising in the extremities. Pulmonary metastases predominate, but
bone metastases, though less common, represent a clinically significant
manifestation associated with pain, pathological fractures and reduced
survival.
Methods:
Narrative
review of textbooks, guidelines and peer-reviewed studies focusing on malignant
soft tissue tumors of the extremities with documented bone metastases.
Results:
Twelve
major tumor types were identified with reported skeletal dissemination,
including synovial sarcoma, undifferentiated pleomorphic sarcoma, liposarcoma,
leiomyosarcoma, rhabdomyosarcoma, extraskeletal Ewing sarcoma, clear cell
sarcoma, angiosarcoma, malignant peripheral nerve sheath tumor, alveolar soft
part sarcoma, fibrosarcoma and extraskeletal osteosarcoma.
Conclusion:
Bone
metastases, though less frequent than pulmonary spread, represent a critical
clinical issue. Awareness of tumor subtypes prone to skeletal dissemination
aids in surveillance and management. Early detection and multimodal treatment
are essential to improve patient outcomes.
Keywords: Soft
tissue sarcoma, Extremities, Bone metastasis, Synovial sarcoma, Rhabdomyosarcoma,
Leiomyosarcoma
1. Introduction
Soft
Tissue Sarcomas (STS) account for less than 1% of adult malignancies but
encompass more than 50 histological subtypes1.
The extremities are the most common site of origin. Metastatic spread typically
involves the lungs; however, bone metastases, though less frequent, are
clinically significant2.Their
incidence varies by histological subtype, with certain sarcomas demonstrating a
higher predilection for skeletal dissemination3.
2. Methods
A narrative literature review was performed using authoritative textbooks, clinical practice guidelines and peer-reviewed studies. Sources were selected to provide a comprehensive overview of malignant soft tissue tumors of the extremities with documented bone metastases.
3. Results
The
following tumor types have been documented to metastasize to bone:
Ø Synovial
sarcoma4
Ø Undifferentiated
pleomorphic sarcoma (malignant fibrous histiocytoma)5
Ø Liposarcoma
(pleomorphic and dedifferentiated subtypes)6
Ø Leiomyosarcoma7
Ø Rhabdomyosarcoma
(alveolar subtype)8
Ø Extraskeletal
Ewing sarcoma9
Ø Clear
cell sarcoma10
Ø Angiosarcoma11
Ø Malignant
Peripheral Nerve Sheath Tumor (MPNST)12
Ø Alveolar
soft part sarcoma3
Ø Fibrosarcoma2
Ø Extraskeletal osteosarcoma6
4. Discussion
Bone
metastases from STS are less frequent than pulmonary involvement but carry
significant morbidity. The incidence ranges from 5% to 10% depending on subtype3,4. Clinical manifestations include pain,
pathological fractures and spinal cord compression.
4.1.
Diagnosis
MRI for local disease, CT/PET for systemic staging and biopsy for confirmation5.
4.2. Management
Surgery for
stabilization or resection of isolated lesions.
Radiotherapy for
palliation and local control.
Systemic therapy (chemotherapy, targeted agents) depending on histology6,8.
4.3. Prognosis
Bone
metastasis generally indicates advanced disease and poorer survival7,8. However, selected patients with limited
skeletal involvement may benefit from aggressive local therapy9.
Future
directions include molecular profiling to identify predictors of skeletal
dissemination and the development of novel targeted therapies.
5. Conclusion
Bone metastases in malignant soft tissue tumors of the extremities, though less common than pulmonary spread, represent a critical clinical issue. Awareness of tumor subtypes prone to skeletal dissemination aids in surveillance and management. Early detection and multimodal treatment are essential to improve patient outcomes.
6. References